Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-Label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Radiprodil in Hepatically Impaired Participants

NCT07457229 is registered in ClinicalTrials.gov with GRIN Therapeutics, Inc. as lead sponsor.

NCT NCT07457229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07457229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-Label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Radiprodil in Hepatically Impaired Participants
Lead sponsor
GRIN Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 3, 2026
Completion date
August 31, 2027
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment